8:30 am Chair’s Opening Remarks

  • Gavin Bennet Head of Pre-Clinical Development, Bicycle Therapeutics

8:40 am Bicycle Conjugates to Target Solid Tumors

  • Gavin Bennet Head of Pre-Clinical Development, Bicycle Therapeutics

Synopsis

  • Bicycles, constrained bicyclic peptides, offer antibody-like affinity and selectivity in a small molecule format
  • Bicycle Toxin Conjugates are now in clinical development, offering rapid tumor penetration with limited plasma exposure
  • Discover how Bicycles can be used to stimulate Immuno-oncology targets such as CD137, which can be targeted to tumor cells using Bicycle tumor-targeted immune cell agonizing molecules (TICAs™)

9:10 am Antibody-Enzyme Fusion Alters Tumor Immuno-Phenotype to Trigger Hyper-Acute Rejection

  • Neil Bander Professor, Weill Cornell - Cornell University

Synopsis

  • Discussing Antibody-enzyme fusion
  • Revising tumor immuno-phenotype
  • Aligning with synthetic immuno-lethality

9:40 am Design of MGTA-117, an Antibody-Drug Conjugate for Stem Cell Conditioning & Transplantation in Malignant Disease & Gene Therapy

  • Nick Yoder Direction, Bioconjugation, Magenta Therapeutics

Synopsis

  • Stem cell transplantation is a potentially curative therapy for life-threatening diseases, yet its use is limited by the need for “conditioning” recipients with intensive chemotherapy or radiation
  • Hear about MGTA-117, an antibody-drug conjugate intended to condition patients by delivering an amanitin payload to CD117-expressing stem cells, while limiting systemic exposure
  • Understand how MGTA-117 incorporates a number of design innovations to maximize effectiveness for transplant conditioning which have been validated by preclinical testing, and clinical data is expected in 2022

10:10 am
Structured Networking

Synopsis

This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the novel format conjugate field and establish meaningful business relationships to pursue for the rest of the conference.

11:00 am
Morning Refreshments

Understanding the State of the Field for Targeted Delivery of RNAs & Other Novel Technologies

11:30 am Pioneering Antibody Oligonucleotide Conjugates for the Treatment of Muscle Disorders

Synopsis

  • Challenges with oligonucleotide delivery
  • Development of antibody oligonucleotide conjugates (AOC) for the delivery of oligonucleotides
  • Application of AOC technology for the treatment of rare genetic disorders of the muscle

12:00 pm Antibody-targeted Cytoplasmic Delivery of Macromolecules Using Sapreme’s Endosomal Escape Enhancers

  • Ruben Postel Founder & Chief Scientific Officer, Sapreme Technologies

Synopsis

  • Novel antibody-based therapeutics
  • Efficient cytoplasmic delivery
  • Platform technology for improved and novel targeted therapies

12:30 pm Harnessing Novel Antibody Oligonucleotide Conjugates as Targeted miRNA Therapy Inhibiting RTK Signaling & Drug Resistance in Head & Neck Cancer

Synopsis

  • miR-30-5p is a critical tumor suppressor in a subset of head and neck cancers targeting multiple Receptor Tyrosine Kinase Pathways
  • MC-30 is a novel targeted therapy mimicking the natural miR-30 gene can reduce drug resistance and may extend progression free survival
  • Novel antibody oligonucleotide conjugates are developed as a promising therapy to treat head and neck cancer

1:00 pm
Lunch & Networking

Understanding the State of the Field for Targeted Delivery of RNAs & Other Novel Technologies

2:00 pm Sharing the Discovery & Functional Optimization of Optimer-drug Conjugates for the Targeting of Antisense Oligonucleotides

Synopsis

  • Optimer binders are oligonucleotide-based affinity ligands that can operate as next-generation delivery vehicles for a diverse range of therapeutic cargo
  • Discovery, conjugation, and optimization processes detail the development of functional Optimer delivery vehicles to target an ASO payload to the kidney
  • Review how developed Optimer delivery vehicles show enhanced delivery and consequent knockdown of expression in preclinical in vitro models, with the necessary biodistribution

Exploring the World of Radio-Conjugates

2:30 pm The Emerging Pillar of Radiopharmaceutical Therapies in Oncology

Synopsis

  • Radiopharmaceutical therapies expected source of business
  • The unique concept of seeing the tumor and treating the tumor
  • Combining the right molecule, with the right isotope, in the right disease area

3:00 pm Establishing Targeted DEP – Platform for Enhanced Targeted Delivery of Chemo & Radioisotopes

  • David Owen Vice President Research & Development, Starpharma

Synopsis

  • Understanding DEP – Dendrimer Enhanced Products including Targeted DEP ADCs and radiotheranostics
  • Evaluate Targeted DEP ADCs’ initial examples in the ADC space – achieving high DAR; enhanced PK/Biodistribution and efficacy outcomes; flexibility in targeting moiety and payload
  • Review Targeted DEP Theranostics – providing superior tumor targeting and better efficacy outcomes; flexibility in targeting moiety and radioisotope of therapeutic or diagnostic applications

3:30 pm Radioactive ADCs in Oncology & Autoimmune Diseases

Synopsis

  • Radioimmunoconjugates are not a new class of drugs but improvements in conjugation technology, choices of isotopes and antibody engineering techniques has generated new interest
  • Highlighting significant opportunities in both diagnostic and therapeutic medicine
  • Outlining a number of recent late-stage developments in this exciting field, as well as potentially important new platform technologies for the future

4:00 pm Chair’s Closing Remarks

4:15 pm
Scientific Poster Session

Synopsis

After the formal presentations have finished for the afternoon, the learning and networking carries on. The Poster Session is allows you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships. During this session scientific posters will be presented on the latest advancements in the novel format conjugates field.